search
Back to results

RDS MultiSense® SpO2 Calibration

Primary Purpose

Hypoxia

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pulse Oximeter, Respiratory Rate, Heart Rate
Sponsored by
Rhythm Diagnostic Systems
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Hypoxia focused on measuring Hypoxia, Pulse Oximetry, SpO2, Remote monitoring, Connected device, Real-time monitoring

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Subject must have the ability to understand and provide written informed consent
  • Subject is 18 to 50 years of age
  • Subject must be willing and able to comply with study procedures and duration
  • Subject is a non-smoker or who has not smoked within 2 days prior to the study.
  • Male or female of any race
  • Subject demographics include a range of skin pigmentations, including at least 3 darkly pigmented subjects or 15% of the subject pool, whichever is larger.

Exclusion Criteria:

  • Subject is considered as being morbidly obese (defined as BMI >39.5)
  • Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites, tattoo in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)
  • Females who are pregnant, who are trying to get pregnant, (confirmed by positive urine pregnancy test unless the subject is known to be not of child-bearing potential)
  • Subjects who have smoked in the last 2 days with COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow)
  • Subjects with known respiratory conditions (self-reported)
  • Subjects with known heart or cardiovascular conditions (self-reported, except for blood pressure and ECG review) or with an implantable active medical device such as pacemaker or automatic defibrillator
  • Self-reported health conditions as identified in the Health Assessment Form (self-reported)
  • Subjects with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)
  • Unwillingness or inability to remove colored nail polish from test digits.
  • Unwillingness to have chest or other test site shaved
  • Other known health condition, should be considered upon disclosure in health assessment form

Sites / Locations

  • Clinimark LLC

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Controled Hypoxia - Healthy volunteer

Arm Description

Male and female subjects, ranging in pigmentation from light to dark

Outcomes

Primary Outcome Measures

Determination of the quality of measurements of arterial blood saturation (SpO2) provided by the MultiSense® system in comparison to measurements made with a reference Pulse Oximetry System, in terms of accuracy.
Accuracy is defined as an average measurement variation less than 3.5% of the mean value to the reference standard. Reference Pulse Oximetry Systems, previously compared to Reference CO-Oximetry will be used as the basis for comparison. The study population will include 15 to 50 subjects. The data for analysis will be equally distributed across the range of 70-100%. All data will be used for the analysis unless identified as unstable by the control oximeter. Data that is found to be unstable will be removed prior to the comparative analysis.

Secondary Outcome Measures

Full Information

First Posted
July 8, 2022
Last Updated
March 28, 2023
Sponsor
Rhythm Diagnostic Systems
Collaborators
Clinimark, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05466942
Brief Title
RDS MultiSense® SpO2 Calibration
Official Title
RDS MultiSense® SpO2 Calibration
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 15, 2022 (Actual)
Primary Completion Date
March 17, 2022 (Actual)
Study Completion Date
April 17, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rhythm Diagnostic Systems
Collaborators
Clinimark, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Data will be collected with the MultiSense® pulse oximetry system during non-motion conditions over the range of 70-100%. A Clinimark reference system, previously correlated to arterial blood CO-Oximetry will be the basis for comparison. A minimum of fifteen (15) up to fifty (50) healthy adult subjects, ranging in pigmentation from light to dark, with at least six (6) subjects with dark pigmentation (Fitzpatrick 5-6), will be enrolled in the study to meet the study design requirements defined by ISO 80601-2-61 and by the FDA's Guidance for Pulse Oximeters (March 4, 2013). SpO2 data will be evaluated during non-motion conditions. SpO2 data will be evaluated during stable step plateaus of induced hypoxic levels. The investigational device will be placed on the thorax of the subjects (patch on the upper back and external electrode on the right pectoral). Simultaneous data collection will be set up for the reference and the systems under test.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoxia
Keywords
Hypoxia, Pulse Oximetry, SpO2, Remote monitoring, Connected device, Real-time monitoring

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Controled Hypoxia - Healthy volunteer
Arm Type
Other
Arm Description
Male and female subjects, ranging in pigmentation from light to dark
Intervention Type
Device
Intervention Name(s)
Pulse Oximeter, Respiratory Rate, Heart Rate
Intervention Description
Measurement of physiological parameters
Primary Outcome Measure Information:
Title
Determination of the quality of measurements of arterial blood saturation (SpO2) provided by the MultiSense® system in comparison to measurements made with a reference Pulse Oximetry System, in terms of accuracy.
Description
Accuracy is defined as an average measurement variation less than 3.5% of the mean value to the reference standard. Reference Pulse Oximetry Systems, previously compared to Reference CO-Oximetry will be used as the basis for comparison. The study population will include 15 to 50 subjects. The data for analysis will be equally distributed across the range of 70-100%. All data will be used for the analysis unless identified as unstable by the control oximeter. Data that is found to be unstable will be removed prior to the comparative analysis.
Time Frame
from device placement to device removal, assessed up to 3 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subject must have the ability to understand and provide written informed consent Subject is 18 to 50 years of age Subject must be willing and able to comply with study procedures and duration Subject is a non-smoker or who has not smoked within 2 days prior to the study. Male or female of any race Subject demographics include a range of skin pigmentations, including at least 3 darkly pigmented subjects or 15% of the subject pool, whichever is larger. Exclusion Criteria: Subject is considered as being morbidly obese (defined as BMI >39.5) Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites, tattoo in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.) Females who are pregnant, who are trying to get pregnant, (confirmed by positive urine pregnancy test unless the subject is known to be not of child-bearing potential) Subjects who have smoked in the last 2 days with COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow) Subjects with known respiratory conditions (self-reported) Subjects with known heart or cardiovascular conditions (self-reported, except for blood pressure and ECG review) or with an implantable active medical device such as pacemaker or automatic defibrillator Self-reported health conditions as identified in the Health Assessment Form (self-reported) Subjects with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported) Unwillingness or inability to remove colored nail polish from test digits. Unwillingness to have chest or other test site shaved Other known health condition, should be considered upon disclosure in health assessment form
Facility Information:
Facility Name
Clinimark LLC
City
Louisville
State/Province
Colorado
ZIP/Postal Code
80027
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

RDS MultiSense® SpO2 Calibration

We'll reach out to this number within 24 hrs